ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (Dec. 1, 2020)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report December 1, 2020, filed under Item 1.01. It states that on December 1, 2020 Arcturus Therapeutics, Inc., a wholly owned subsidiary, and Western Alliance Bank entered into a Fourth Amendment to the Loan and Security Agreement dated October 12, 2018. The report says the amendment was executed to permit the granting of a limited security interest in certain assets of Arcturus to the lender under the previously disclosed Manufacturing Support Agreement, dated November 7, 2020, with the Economic Development Board of the Republic of Singapore. The amendment is Exhibit 10.1. The signature block shows /s/ Joseph E. Payne, Chief Executive Officer, dated December 7, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event
reported): December 1, 2020

ARCTURUS
THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified
in its charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive , Suite 250

San Diego , California 92121

(Address of principal executive offices)

Registrant’s telephone number,
including area code: (858) 900-2660

(Former name or former address, if changed
since last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On December 1, 2020, Arcturus Therapeutics, Inc. (“Arcturus”),
a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc., and Western Alliance Bank (the “Bank”) entered into
a Fourth Amendment (the “Fourth Amendment”) to the Loan and Security Agreement dated October 12, 2018 (the “Loan
Agreement”) between the Bank and the Borrower.

The Fourth Amendment was executed to permit the granting of
a limited security interest in certain assets of Arcturus to the lender under the previously disclosed Manufacturing Support Agreement,
dated November 7, 2020, with the Economic Development Board of the Republic of Singapore.

The foregoing description of the Fourth Amendment is not a complete
description of all terms and is qualified in its entirety by reference to the full text of the Fourth Amendment, attached hereto
as Exhibit 10.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description of Exhibit
10.1 | Fourth Amendment to Loan and Security Agreement, dated December 1, 2020
104 | Cover Page to this Current Report on Form 8-K in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: December 7, 2020
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2020-12-07_0001193805-20-001498.htm

Size

21,815 bytes

SHA-256

67127d3b3192d78b9da41385e011bee702331ab606e01fb4b05c20393ace4e84

Our copy

SEC_ARCT_8-K_filed2020-12-07_0001193805-20-001498.htm

Original

www.sec.gov